FIELD: biotechnologies.
SUBSTANCE: method is disclosed for production of a wild type of an attenuated or recombinant pox virus, without detected infectitious specificity. The method provides for preparation of a culture of packing cells, contamination with pox virus and cultivation of infected cells. Further EEV particles are extracted from a culture supernatant and from packing cells, treatment of a mixture of pox virus particles, concentration of a treated mixture of pox virus particles and diafiltration of a concentrated mixture of pox virus particles.
EFFECT: produced pox virus particles are used for production of medicinal agents.
8 cl, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF POX VIRUSES AND COMPOSITION OF POX VIRUSES | 2013 |
|
RU2581910C2 |
| METHOD OF OBTAINING POXVIRUSES AND COMPOSITIONS OF POXVIRUSES | 2007 |
|
RU2551982C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMPOSITIONS AND METHODS FOR INCREASING THE STABILITY OF TRANSGENES IN POXVIRUSES | 2017 |
|
RU2756534C2 |
| POX VIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2557312C2 |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE | 2015 |
|
RU2724433C2 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| RECOMBINANT VIRAL VACCINE | 2007 |
|
RU2453335C2 |
| BIOMARKER FOR PATIENT'S MONITORING | 2010 |
|
RU2542435C2 |
